July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Naïve pluripotency improves human diabetic iPSC derived-vascular progenitor cell engraftment and migration in an ischemic retinopathy mouse model
Author Affiliations & Notes
  • Tea Soon Park
    Pediatric Oncology, Johns Hopkins University, Baltimore, Maryland, United States
  • Ludovic Zimmerlin
    Pediatric Oncology, Johns Hopkins University, Baltimore, Maryland, United States
  • Imran Ahmed Bhutto
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland, United States
    Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
  • Riya Kanherkar
    Pediatric Oncology, Johns Hopkins University, Baltimore, Maryland, United States
  • Rebecca Evans-Moses
    Pediatric Oncology, Johns Hopkins University, Baltimore, Maryland, United States
  • Gerard A Lutty
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland, United States
  • Elias T Zambidis
    Pediatric Oncology, Johns Hopkins University, Baltimore, Maryland, United States
  • Footnotes
    Commercial Relationships   Tea Soon Park, None; Ludovic Zimmerlin, None; Imran Bhutto, None; Riya Kanherkar, None; Rebecca Evans-Moses, None; Gerard Lutty, None; Elias Zambidis, Thermo Fisher Scientific (F)
  • Footnotes
    Support  TEDCO 2014-MSCRFE-118153 (TSP), U01HL099775 (ETZ), NIH/NEI R01EY023962 (ETZ)), NIH/NICHD R01HD082098 (ETZ), TEDCO 2013-MSCRFII-0032-00 (ETZ), and Novo Nordisk Diabetes & Obesity Science Forum Award, EY001765 (Wilmer Core Grant for Vision Research)
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2792. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tea Soon Park, Ludovic Zimmerlin, Imran Ahmed Bhutto, Riya Kanherkar, Rebecca Evans-Moses, Gerard A Lutty, Elias T Zambidis; Naïve pluripotency improves human diabetic iPSC derived-vascular progenitor cell engraftment and migration in an ischemic retinopathy mouse model. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2792.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Human iPSC (hiPSC) could provide unlimited amounts of embryonic-like vascular progenitors (VP) to repair ischemic diabetic tissue. However, clinical translation would require safe, efficient and reproducible reprogramming and differentiation into functional VP. We recently defined a human naïve pluripotent state using LIF and chemical inhibitors of WNT, MEK and tankyrase (LIF-3i). LIF-3i has been validated in >30 genetic backgrounds and recapitulates transcriptomic, epigenetic, and signaling signatures of the pre-implantation epiblast. LIF-3i cells tolerate direct differentiation without re-priming, with reduced interline variability and lineage bias, and improved multi-lineage capacity. The purpose of this study was to test the therapeutic potential of VP generated from patient-specific naïve hiPSC.

Methods : Type-I diabetic skin fibroblasts (D-hiPSC) were reprogrammed using a non-integrative episomal 7-factor system and conventional E8 primed culture medium. Exposure to a GSK3β inhibitor and ascorbic acid facilitated reprogramming kinetics. Three D-hiPSC lines were reverted in LIF-3i and differentiated into VP (i.e, APEL medium) in parallel with isogenic primed controls. Functional capacity of D-hiPSC-derived VP was assessed by cell cycle, acetylated-Dil-LDL uptake, Matrigel-tube and -plug assays, pH2AX foci quantification after neocarzinostatin exposure, and vascular engraftment in an ischemic retinopathy (IR) mouse model.

Results : Naive D-hiPSC rapidly acquired expressions associated with naïve pluripotency (e.g., pSTAT3, DNMT3L, NR5A2, and DPPA3) and produced CD31+CD146+ VP cells at higher efficiencies than isogenic primed controls. Long-term cultures of naïve-D-hiPSC-derived VP displayed superior proliferation, reduced senescence and higher resistance to DNA damage. Greater numbers of naïve D-hiPSC-VP were detected in the retinas of an IR mouse model up to 4 weeks after intravitreal injection. At 1-week post-transplantation, human naïve D-iPSC-VP migrated efficiently in superficial and deep retinal blood vessels. In contrast, isogenic primed D-iPSC-VP remained in superficial layers of retina.

Conclusions : Our results suggest that the LIF-3i naïve reversion dramatically improves the differentiation efficiency, functionality, and therapeutic potential of VP generated from diabetic patient hiPSC.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×